BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23295255)

  • 1. Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy.
    Oh SY; Kwon HC; Kim SH; Lee S; Lee JH; Graves CA; Camphausen K; Kim HJ
    Chemotherapy; 2012; 58(6):426-34. PubMed ID: 23295255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer.
    Oh SY; Kwon HC; Kim SH; Lee S; Lee JH; Hwang JA; Hong SH; Graves CA; Camphausen K; Kim HJ; Lee YS
    BMC Cancer; 2013 Feb; 13():43. PubMed ID: 23374220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX.
    Oh SY; Shin A; Kim SG; Hwang JA; Hong SH; Lee YS; Kwon HC
    Oncotarget; 2016 May; 7(21):31204-14. PubMed ID: 27144430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
    Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
    BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.
    De Vita F; Orditura M; Matano E; Bianco R; Carlomagno C; Infusino S; Damiano V; Simeone E; Diadema MR; Lieto E; Castellano P; Pepe S; De Placido S; Galizia G; Di Martino N; Ciardiello F; Catalano G; Bianco AR
    Br J Cancer; 2005 May; 92(9):1644-9. PubMed ID: 15856038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status.
    Petrioli R; Francini E; Roviello F; Marrelli D; Miano ST; Fiaschi AI; Laera L; Bellini MA; Roviello G
    J Geriatr Oncol; 2015 Sep; 6(5):380-6. PubMed ID: 26228711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
    Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
    Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
    Yan D; Dai H
    Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):217-9. PubMed ID: 19615264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
    Tsuji K; Yasui H; Onozawa Y; Boku N; Doyama H; Fukutomi A; Yamazaki K; Machida N; Todaka A; Taniguchi H; Tsushima T; Yokota T
    Jpn J Clin Oncol; 2012 Aug; 42(8):686-90. PubMed ID: 22693245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
    Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
    Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.
    Cho YH; Kim SY; Hong Lee M; Yoo MW; Bang HY; Lee KY; Yoon SY
    Gastric Cancer; 2012 Oct; 15(4):389-95. PubMed ID: 22237658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
    Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
    Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOLFOX (oxaliplatin and 5 fluorouracil/leucovorin) in patients with untreated metastatic gastric adenocarcinoma Phase II study.
    Mohammad HA; Magdy FM; Mahmoud OM
    Indian J Cancer; 2011; 48(4):460-5. PubMed ID: 22293261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.
    el Aziz LM
    Med Oncol; 2014 Dec; 31(12):311. PubMed ID: 25367855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
    Kondoh C; Kadowaki S; Komori A; Narita Y; Taniguchi H; Ura T; Ando M; Muro K
    Gastric Cancer; 2018 Nov; 21(6):1050-1057. PubMed ID: 29658055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
    Sun Z; Zhang N
    World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma.
    Yan D; Dai H; Liu JW
    BMC Cancer; 2011 Apr; 11():151. PubMed ID: 21513571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin, 5Fluorouracil and Leucovorin (FOLFOX4) as First Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer.
    Haghighi S; Kasbkar H; Esmaeilpour K; Yasaei M
    Asian Pac J Cancer Prev; 2016; 17(7):3277-80. PubMed ID: 27509963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified FOLFOX-4 as first-line and salvage treatment in advanced gastric cancer.
    Baek YH; Choi SR; Jang JS; Roh MH; Lee JH; Won JJ; Lee CM
    Hepatogastroenterology; 2011; 58(105):251-6. PubMed ID: 21510324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.